No Result

View All Result

No products in the cart.

2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑

Home StudyGraphics

#VisualAbstract Polatuzumab vedotin plus obinutuzumab and lenalidomide shows high complete response rates in patients with relapsed or refractory follicular lymphoma

Phase 1b/2 study (multi-centre, single-arm)

byKathleen Lau

December 2, 2021

in StudyGraphics

Reading Time: 1 min read

$#VisualAbstract Polatuzumab vedotin plus obinutuzumab and lenalidomide shows high complete response rates in patients with relapsed or refractory follicular lymphoma$

High-titre convalescent plasma therapy not effective against severe COVID-19 pneumonia

RelatedReports

Chronic Disease

The use of neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer may reduce mortality

September 22, 2026

Oncology

Daraxonrasib extends survival in metastatic pancreatic cancer

September 17, 2026

Cardiology

Borderline-low hemoglobin levels linked to increased mortality

September 14, 2026

Hematology

N-methylaniline exposure identified as likely cause of methemoglobinemia during maritime migration

September 13, 2026

Mutation linked with decrease in cutaneous diffuse large B-cell lymphoma

Epcoritamab shows promising response rates seen in relapsed or refractory non-Hodgkin lymphoma

Surgical site anesthetic infusion may enhance analgesia after mastectomy

Peripherally inserted central catheters are associated with twice as many complications than midline catheters when used short-term

AAP recommends focus on nutrient-rich foods in schools

Smartphone-based intervention reduced body mass index and obesity in school children

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result

#VisualAbstract Polatuzumab vedotin plus obinutuzumab and lenalidomide shows high complete response rates in patients with relapsed or refractory follicular lymphoma

Phase 1b/2 study (multi-centre, single-arm)

The use of neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer may reduce mortality

Daraxonrasib extends survival in metastatic pancreatic cancer

Borderline-low hemoglobin levels linked to increased mortality

High-titre convalescent plasma therapy not effective against severe COVID-19 pneumonia

Epcoritamab shows promising response rates seen in relapsed or refractory non-Hodgkin lymphoma

RelatedReports

The use of neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer may reduce mortality

Daraxonrasib extends survival in metastatic pancreatic cancer

Borderline-low hemoglobin levels linked to increased mortality

N-methylaniline exposure identified as likely cause of methemoglobinemia during maritime migration

Epcoritamab shows promising response rates seen in relapsed or refractory non-Hodgkin lymphoma

Peripherally inserted central catheters are associated with twice as many complications than midline catheters when used short-term

Smartphone-based intervention reduced body mass index and obesity in school children

2MM+ All Access

Recent Reports

The medical literature, distilled daily.

Membership benefits

#VisualAbstract Polatuzumab vedotin plus obinutuzumab and lenalidomide shows high complete response rates in patients with relapsed or refractory follicular lymphoma

Phase 1b/2 study (multi-centre, single-arm)

RELATED REPORTS

High-titre convalescent plasma therapy not effective against severe COVID-19 pneumonia

Epcoritamab shows promising response rates seen in relapsed or refractory non-Hodgkin lymphoma

RelatedReports

2MM+ All Access

Recent Reports

The medical literature, distilled daily.

Membership benefits